$17.6 Million is the total value of CAXTON CORP's 11 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | XERIS BIOPHARMA HOLDINGS INC | $11,300,499 | -14.8% | 5,113,348 | -9.4% | 64.38% | -10.0% | |
| RZLT | REZOLUTE INC | $3,363,366 | +156.9% | 1,318,967 | 0.0% | 19.16% | +171.2% | |
| SPY | Buy | SPDR S&P 500 ETF TRtr unit | $970,988 | +54.6% | 1,856 | +40.4% | 5.53% | +63.1% |
| BRKB | Sell | BERKSHIRE HATHAWAY INC DELcl b new | $428,308 | +16.0% | 1,019 | -1.5% | 2.44% | +22.4% |
| New | KYVERNA THERAPEUTICS INC | $393,614 | – | 15,846 | +100.0% | 2.24% | – | |
| MOLECULAR TEMPLATES INC | $306,580 | -39.9% | 136,866 | 0.0% | 1.75% | -36.6% | ||
| New | MIND MEDICINE MINDMED INC | $273,207 | – | 29,065 | +100.0% | 1.56% | – | |
| Sell | ABIVAX SAsponsored ads | $226,055 | +26.2% | 15,808 | -5.6% | 1.29% | +33.2% | |
| LEXEO THERAPEUTICS INC | $161,796 | +16.8% | 10,319 | 0.0% | 0.92% | +23.3% | ||
| CMPX | COMPASS THERAPEUTICS INC | $86,062 | +26.9% | 43,465 | 0.0% | 0.49% | +33.9% | |
| ACET | New | ADICET BIO INC | $41,096 | – | 17,488 | +100.0% | 0.23% | – |
| ALLK | Exit | ALLAKOS INC | $0 | – | -24,710 | -100.0% | -0.36% | – |
| Exit | HARPOON THERAPEUTICS INC | $0 | – | -13,176 | -100.0% | -0.70% | – | |
| Exit | APOGEE THERAPEUTICS INC | $0 | – | -7,353 | -100.0% | -1.11% | – | |
| SVRA | Exit | SAVARA INC | $0 | – | -353,441 | -100.0% | -8.97% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| BERKSHIRE HATHAWAY INC DEL | 20 | Q2 2024 | 5.8% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| REZOLUTE INC | 15 | Q2 2024 | 28.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Savara Inc | February 13, 2024 | 353,441 | 0.3% |
| SCYNEXIS INCSold out | February 13, 2024 | 0 | 0.0% |
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.